ArticleGenome biology2026
Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Consolidated Evidence and New Frontiers of Liquid Biopsy in Lung Cancer: A Narrative Review.Cells · 2026Review
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAltered circulating cell-free DNA (cfDNA) fragmentation patterns serve as cancer biomarkers, yet standard short-read sequencing fails to capture the full fragment-length spectrum. Although cancer patients often exhibit elevated cfDNA, the relationship between high cfDNA concentration and altered fragmentation remains poorly defined. To address this question, we leverage Oxford Nanopore (ONT) sequencing, which captures the full fragment-length spectrum and enables cell type inference via DNA methylation markers.
resultsWe perform ONT whole-genome sequencing on a pan-cancer cohort and a neuroendocrine cancer cohort, both with elevated cfDNA levels. In both cohorts, the highest cfDNA levels are characterized by either hypofragmentation or hyperfragmentation. Hypofragmented samples (characterized by 1-4 kb fragments) exhibit hallmarks of DNASE1L3-mediated fragmentation due to blood-derived DNA release during delayed blood processing, while samples with ultra-long fragments (> 7.5 kb) indicate release due to cell lysis during plasma processing. In contrast, the short (<145 bp) fragments of hyperfragmented cancer samples are not artifactual, and they are characterized by elevated levels of both cancer- and blood-derived DNA, suggesting an inflammatory or other systemic response as opposed to a cancer-specific fragmentation mechanism.
conclusionsThese findings differentiate biological from artifactual fragmentation, broaden our understanding of high cfDNA levels and hyperfragmentation in cancer, and establish long-read sequencing as a robust tool for biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.